The mechanism of COVID-19 associated coagulopathy: a prospective cohort study
- Conditions
- Patients admitted with COVID-19
- Registration Number
- JPRN-UMIN000042717
- Lead Sponsor
- Tohoku university
- Brief Summary
o difference was found in the EV levels between the non-coagulopathy and coagulopathy groups.We conducted three group comparison, COVID-19 coagulopathy group, non-coagulopathy group, and healthy volunteer. In the Kruskal Wallis test, the CD41 positive EV levels were statistically different among the groups. The coagulopathy group had higher CD41 positive EV levels than the healthy volunteer group.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 99
Not provided
(1) patients in which informed consent could not be obtained from the person or close relatives (2) patients who have other infectious diseases (3) patients with end-stage heart failure( defined as NYHA class4) (4) patients with end-stage liver failure (defined as Child-Pugh classification C) (5) patients with progressive cancer, or patients undergoing cancer treatment (6) patients who are pregnant (7) patients who have participated in this study (8) patients who are diagnosed as COVID-19 accidentally and need emergency treatment for other diseases
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method